BRIEF published on 12/17/2025 at 11:02, 2 months 3 days ago Valerio Therapeutics Welcomes Professor Eric Vivier to its Board of Directors Board Of Directors Oncology Immunology Valerio Therapeutics Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 2 months 3 days ago Valerio Therapeutics Accueille le Professeur Eric Vivier au Conseil d'Administration Conseil D'administration Oncologie Valerio Therapeutics Immunologie Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 2 months 3 days ago Valerio Therapeutics nomme le professeur Eric Vivier observateur au conseil d'administration Conseil D'administration Valerio Thérapeutique Immunologie Professeur Eric Vivier Stratégie En Oncologie
BRIEF published on 12/17/2025 at 11:02, 2 months 3 days ago Valerio Therapeutics Appoints Professor Eric Vivier as Board Observer Board Of Directors Immunology Valerio Therapeutics Professor Eric Vivier Oncology Strategy
PRESS RELEASE published on 12/17/2025 at 10:57, 2 months 3 days ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce la désignation du Professeur Eric Vivier en qualité d'Observateur de son Conseil d’Administration. Le Professeur apportera son expertise en immunologie pour développer des traitements innovants en oncologie Conseil D'administration Valerio Therapeutics Immunologie Professeur Eric Vivier Observateur
PRESS RELEASE published on 12/17/2025 at 10:57, 2 months 3 days ago Inside Information / Other news releases Valerio Therapeutics appoints Prof. Eric Vivier as Observer to Board of Directors. Prof. Vivier, a renowned immunologist, will bring over 30 years of experience to drive innovative tumor treatment approaches Board Of Directors Valerio Therapeutics Professor Eric Vivier Immunologist Tumor Treatment
PRESS RELEASE published on 10/30/2025 at 09:04, 3 months 21 days ago Rapport financier semestriel 2025
BRIEF published on 10/30/2025 at 09:03, 3 months 21 days ago Bilan financier et stratégique de Valerio Therapeutics pour le 1er semestre 2025 Recentrage Stratégique Valerio Therapeutics Résultats Financiers 2025 Plateformes V-Body Recherche Partenariats
BRIEF published on 10/30/2025 at 09:03, 3 months 21 days ago Valerio Therapeutics' financial and strategic review for the first half of 2025 Strategic Refocusing Valerio Therapeutics 2025 Financial Results V-Body Platforms Seeking Partnerships
Published on 02/20/2026 at 18:30, 14 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 2 hours 59 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 4 hours 14 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 4 hours 36 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 4 hours 44 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 8 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 13 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 44 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 44 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 09:28, 9 hours 16 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026
Published on 02/20/2026 at 09:28, 9 hours 16 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
